President, Chief Executive Officer and Chairman of the Board, Revolution Medicines
Search every verified Mark Goldsmith interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Mark Goldsmith, president, CEO and chairman of Revolution Medicines, has discussed the company's recent FDA-approved pancreatic cancer drug Rasonque (daraxonrasib) in multiple media appearances. He described the drug as a "practice-changing targeted medicine" and a "breakthrough, first-in-class" treatment that targets RAS proteins, which he called the main cause of pancreatic cancer. Goldsmith stated the company is committed to ensuring access for eligible U.S. patients regardless of ability to pay, while acknowledging the drug's price of nearly $480,000 per year reflects its differentiated clinical profile. He also noted early clinical trial results showing the drug shrank tumors in some patients with advanced lung cancer. Goldsmith discussed the drug's development history, saying Revolution Medicines pursued RAS despite it being considered difficult to drug for over 40 years, and that the company followed the science rather than accepted prevailing views that pancreatic cancer was "invincible." He said the company aims to eventually make RAS-driven cancers chronically managed diseases. On broader industry topics, Goldsmith said artificial intelligence and machine learning will be important across drug discovery, development, and delivery, and he commented on global competition, noting China has a government-sponsored effort to become competitive in biotech while raising concerns about intellectual property practices there.
After FDA approval of its breakthrough cancer drug Rasonque, Revolution Medicines has pledged to ensure access for all eligible US patients regardless of their ability to pay. Chief executive Mark Goldsmith shares how the company is making it possible and what is next for the company. #Rasonque #Cancer #WSJ
Welcome to the Oncology Brothers podcast! In this episode, we dove deep into the groundbreaking advancements in pancreatic cancer treatment, focusing on the recent approval of daraxonrasib. Join us as we welcome Mark Goldsmith, MD, PhD, CEO of Revolution Medicines, who shared his inspiring journey from clinical practice to the biotech industry. Discover the challenges and triumphs behind bringing this first-in-class drug to market, and learn about the significant impact it has on patient outcomes. Listen us on: Spotify: https://open.spotify.com/show/31BXhY9... Apple Podcast: https://podcasts…
Revolution Medicines CEO Dr. Mark Goldsmith discusses the clinical trial results from Rasonque on ‘FBN’s Wall Street.’ #fox #media #breakingnews #us #usa #new #news #breaking #foxbusiness #fbnswallstreet #markgoldsmith #goldsmith #revolutionmedicines #rasonque #cancer #cancertreatment #clinicaltrial #biotech #biotechnology #healthcare #medicalresearch #medicine #pharmaceuticals #investing Subscribe to Fox Business: https://bit.ly/2D9Cdse Watch more Fox Business Video: https://video.foxbusiness.com Watch Fox Business Network Live: http://www.foxnewsgo.com/ FOX Business Network (FBN) is a fi…
For decades, RAS mutations drove more than 90% of pancreatic tumors with no viable therapeutic target. That is now changing. Break Through Cancer’s Conquering KRAS in Pancreatic Cancer TeamLab has spent years generating deep molecular data on advanced pancreatic cancer in the laboratory and through a first-of-its-kind clinical trial assessing daraxonrasib – an investigational multi-selective RAS(ON) inhibitor. The TeamLab’s clinical trial studies paired pre- and on-treatment biopsies and blood samples to understand how tumors respond, adapt, and resist at the molecular level. In this convers…
Sign in to search the full transcript archive, filter by topic, and access every quote from Mark Goldsmith.
The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →
Pro unlocks every transcript in full, plus unlimited search across every executive and company we cover.
50% off appliedPulling data at scale? The Data API gives you 30,000 transcripts a month over REST, MCP and JSON.
Compare all plans